1. Auquier, P., Lancon, C., Rouillon, F., Lader, M. and Holmes, C. Mortality in schizophrenia. Pharmacoepidemiol Drug Saf 2006; 15(12): 873-9.
2.
Charlson, F.J., Ferrari, A.J., Santomauro, D.F., Diminic, S., Stockings, E., Scott et al., Global Epidemiology and Bur den of Schizophrenia: Findings From the Global Burden of Disease Study 2016. Schizophrenia Bulletin 2018; 44(6): 1195-1203.
3.
Chesney, E., Goodwin, G.M. and Fazel, S. Risks of all-cause and suicide mortality in mental disorders: a meta-review. World Psychiatry 2014; 13(2): 153-160.
4.
Crump, C., Winkleby, M.A., Sundquist, K. and Sundquist, J. Comorbidities and Mortality in Persons With Schizophre nia: A Swedish National Cohort Study. American Journal of Psychiatry 2013; 170(3): 324-333.
5.
Galderisi, S., Bucci, P., Ucok, A. and Peuskens, J. No gender differences in social outcome in patients suffering from schizophrenia. European Psychiatry 2012; 27(6): 406-408.
6.
Gogos, A., Ney, L.J., Seymour, N., Van Rheenen, T.E. and Fel mingham, K.L. Sex differences in schizophrenia, bipolar disorder, and post-traumatic stress disorder: Are gonadal hormones the link? British Journal of Pharmacology 2019; 176(21): 4119-4135.
7.
Jaaskelainen, E., Juola, P., Hirvonen, N., McGrath, J.J., Saha, S., Isohanni, M., Veijola, J. and Miettunen, J. A Systematic Review and Meta-Analysis of Recovery in Schizophrenia. Schizophrenia Bulletin 2013; 39(6): 1296-1306.
8.
Kahn, R.S., Sommer, I.E., Murray, R.M., Meyer-Lindenberg, A., Weinberger, D.R., Cannon i wsp., Schizophrenia. Nature Reviews Disease Primers 2015; 1.
9.
Kay, S.R., Fiszbein, A. and Opler, L.A. The positive and ne gative syndrome scale (PANSS) for schizophrenia. Schizo phrenia Bulletin 1987; 13(2): 261-276.
10.
Kirschner, M., Aleman, A. and Kaiser, S. Secondary nega tive symptoms - A review of mechanisms, assessment and treatment. Schizophr Res 2017; 186: 29-38.
11.
Koster, A., Lindhardt, A., Lajer, M. and Rosenbaum, B. Gen der differences in first episode psychosis. Social Psychiatry and Psychiatric Epidemiology 2008; 43(12): 940-946.
12.
Leucht, S., Corves, C., Arbter, D., Engel, R.R., Li. i wsp., Second generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373(9657): 31-41.
13.
Lora, A., Kohn, R., Levav, I., McBain, R., Morris, J. and Sa xena, S. Service availability and utilization and treatment gap for schizophrenic disorders: a survey in 50 low- and middle-income countries. Bulletin of the World Health Or ganization 2012; 90(1): 47-54.
14.
McGrath, J., Saha, S., Welham, J., El Saadi, O., MacCauley, C. and Chant, D. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology 2004; Bmc Medicine, 2.
15.
Meltzer, H.Y., Alphs, L., Green, A.I., Altamura, A.C., Anand, R., Bertoldi, A. et al., Clozapine treatment for suicidality in schizophrenia - International Suicide Prevention Trial (In terSePT). Archives of General Psychiatry 2003; 60(1): 82-91.
16.
Ochoa, S., Usall, J., Cobo, J., Labad, X. and Kulkarni, J. Gender differences in schizophrenia and first-episode psychosis: a comprehensive literature review. Schizophr Res Treatment 2012; 916198.
17.
Piotrowski, P., Gondek, T.M., Krolicka-Deregowska, A., Mi siak, B., Adamowski, T. and Kiejna, A. Causes of mortality in schizophrenia: an updated review of European studies. Psychiatria Danubina 2017; 29(2): 108-120.
18.
Pompili, M., Amador, X.F., Girardi, P., Harkavy-Friedman, J., Harrow, M., Kaplan, K. et al., Suicide risk in schizophre nia: learning from the past to change the future. Ann Gen Psychiatry 2007; 6-10.
19.
Saha, S., Chant, D. and McGrath, J. A systematic review of mor tality in schizophrenia: is the differential mortality gap wor sening over time? Arch Gen Psychiatry 2007; 64(10): 1123-31.
20.
Saha, S., Chant, D., Welham, J. and McGrath, J. A systematic review of the prevalence of schizophrenia. Plos Medicine 2005; 2(5): 413-433.
21.
Simms, J., McCormack, V., Anderson, R. and Mulholland, C. Correlates of self-harm behaviour in acutely ill patients with schizophrenia. Psychology and Psychotherapy-Theory Research and Practice 2007; 80: 39-49.
22.
Sun, J., Walker, A.J., Dean, B., van den Buuse, M. and Gogos, A. Progesterone: The neglected hormone in schizophrenia? A focus on progesterone-dopamine interactions. Psychoneu roendocrinology 2016; 74: 126-140.
23.
Szulc, A., Dudek, D., Samochowiec, J., Wojnar, M., Heitzman, J. and Gałecki, P. Recommendations for the treatment of schizophrenia with negative symptoms. Standards of phar macotherapy by the Polish Psychiatric Association (Polskie Towarzystwo Psychiatryczne), part 2. Psychiatr Pol 2019; 53(3): 525-540.
24.
Szymanski, S., Lieberman, J.A., Alvir, J.M., Mayerhoff, D., Loebel, A., Geisler, S. i wsp., Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. American Journal of Psychiatry 1995; 152(5): 698-703.
25.
Zhang, X.Y., Chen, D.C., Xiu, M.H., Yang, F.D., Haile, C.N., Kosten, T.A. i wsp., Gender Differences in Never-Medicated First-Episode Schizophrenia and Medicated Chronic Schizo phrenia Patients. Journal of Clinical Psychiatry 2012; 73(7): 1025-1033
